MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329103 | Name: Mosapramine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mosapramine, also known as Clospipramine and Y-516, is a dopamine D2-receptor antagonist used for the treatment of schizophrenia. The affinities of mosapramine for D4 receptors is 8 times higher than that of clozapine, and the affinity for D3 receptors is 40 times higher than that of raclopride.

Chemical Structure

Mosapramine
Mosapramine
CAS#89419-40-9

Theoretical Analysis

MedKoo Cat#: 329103

Name: Mosapramine

CAS#: 89419-40-9

Chemical Formula: C28H35ClN4O

Exact Mass: 478.2499

Molecular Weight: 479.07

Elemental Analysis: C, 70.20; H, 7.36; Cl, 7.40; N, 11.70; O, 3.34

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Mosapramine; Y-516; Y 516; Y516; Cremin; Clospipramine
IUPAC/Chemical Name
1'-(3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)hexahydro-2H-spiro[imidazo[1,2-a]pyridine-3,4'-piperidin]-2-one
InChi Key
PXUIZULXJVRBPC-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H35ClN4O/c29-23-12-11-22-10-9-21-6-1-2-7-24(21)32(25(22)20-23)16-5-15-31-18-13-28(14-19-31)27(34)30-26-8-3-4-17-33(26)28/h1-2,6-7,11-12,20,26H,3-5,8-10,13-19H2,(H,30,34)
SMILES Code
O=C1NC2CCCCN2C13CCN(CCCN4C5=CC(Cl)=CC=C5CCC6=CC=CC=C64)CC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 479.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kishi T, Matsunaga S, Matsuda Y, Iwata N. Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine. Neuropsychiatr Dis Treat. 2014 Dec 10;10:2339-51. doi: 10.2147/NDT.S73464. eCollection 2014. PubMed PMID: 25525363; PubMed Central PMCID: PMC4266422. 2: Fujimura M, Hashimoto K, Yamagami K. The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain: comparison with haloperidol, clozapine and risperidone. Life Sci. 2000 Oct 27;67(23):2865-72. PubMed PMID: 11106001. 3: Futamura T, Shimokawa T, Morio Y, Haga K, Fukuda T. [Quantitative autoradiographic analysis of the binding of mosapramine to dopamine D3-receptors]. Nihon Yakurigaku Zasshi. 1995 Nov;106(5):339-46. Japanese. PubMed PMID: 8566910. 4: Takahashi N, Terao T, Oga T, Okada M. Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. Neuropsychobiology. 1999;39(2):81-5. PubMed PMID: 10072664. 5: Futamura T, Ohashi Y, Yano K, Takahashi Y, Haga K, Fukuda T. [The affinities of mosapramine for the dopamine receptor subtypes in human cell lines expressing D2, D3 and D4 receptors]. Nihon Yakurigaku Zasshi. 1996 May;107(5):247-53. Japanese. PubMed PMID: 8690306. 6: Tashiro C, Yuasa S, Fukuda T. [Synthesis of metabolites of mosapramine. II. Synthesis of phenolic metabolites of mosapramine and their pharmacological activities]. Yakugaku Zasshi. 1992 Sep;112(9):615-21. Japanese. PubMed PMID: 1361567. 7: Tashiro C, Setoguchi S, Fukuda T, Marubayashi N. Syntheses and biological activities of optical isomers of 3-chloro-5-[3-(2-oxo-1,2,3,5,6,7,8,8a-octahydroimidazo[1,2-a]pyridine- 3-spiro-4'-piperidino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine (mosapramine) dihydrochloride. Chem Pharm Bull (Tokyo). 1993 Jun;41(6):1074-8. PubMed PMID: 8103712. 8: Uchihashi Y, Morimoto T, Tadokoro S. [Effects of mosapramine (Y-516), a new dopamine D2 antagonist, on reverse tolerance after repeated administration of methamphetamine by means of the ambulation-increasing effect in mice]. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):153-60. Japanese. PubMed PMID: 1505855. 9: Tashiro C, Yuasa S, Demizu K. [Synthesis of metabolites of mosapramine. I. Synthesis of alcoholic metabolites]. Yakugaku Zasshi. 1992 Feb;112(2):108-14. Japanese. PubMed PMID: 1355558. 10: Kishi T, Matsuda Y, Matsunaga S, Iwata N. Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2015 Feb 20;11:419-34. doi: 10.2147/NDT.S78977. eCollection 2015. PubMed PMID: 25759585; PubMed Central PMCID: PMC4345995. 11: Kishi T, Matsuda Y, Iwata N. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014 Feb 4;9(2):e88049. doi: 10.1371/journal.pone.0088049. eCollection 2014. PubMed PMID: 24505373; PubMed Central PMCID: PMC3913743. 12: Kishi T, Iwata N. Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2013 Sep;27(9):731-41. doi: 10.1007/s40263-013-0085-7. Review. PubMed PMID: 23812802. 13: Sumiyoshi T, Suzuki K, Sakamoto H, Yamaguchi N, Mori H, Shiba K, Yokogawa K. Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy. Neuropsychopharmacology. 1995 Feb;12(1):57-64. PubMed PMID: 7766287. 14: Onrust SV, McClellan K. Perospirone. CNS Drugs. 2001;15(4):329-37; discussion 338. Review. PubMed PMID: 11463136. 15: Morimoto T, Morimoto Y, Fukuda T, Setoguchi M. [Effect of Y-516 on the hyperactivity induced by dopamine injected bilaterally into the nucleus accumbens]. Nihon Yakurigaku Zasshi. 1990 Aug;96(2):65-71. Japanese. PubMed PMID: 2227720.